K S Vaddadi1, E Soosai, G Vaddadi. 1. Department of Psychological Medicine (Monash University), Monash Medical Centre, 246 Clayton Road, Clayton, Victoria 3168, Australia. vaddadi@hotmail.com
Abstract
AIMS: To compare plasma and red-cell selenium concentrations of schizophrenic patients treated withclozapine, with healthy controls and patients with mood disorders. METHODS:Plasma and red-cell selenium concentrations were measured in random venous blood samples from four groups: mood disorder (n = 36), schizophrenics treated with clozapine (n = 54), schizophrenics not treated with clozapine (n = 41) and a healthy control group (n = 56). Assays were performed by an independent laboratory that was blinded to the patient groups and specializes in estimating trace metal concentrations. RESULTS:Selenium concentrations in plasma and red cells were found to be significantly lower in schizophrenic patients treated withclozapine as compared with all other groups. CONCLUSIONS:Selenium is an essential antioxidant. Its deficiency has been implicated in myocarditis and cardiomyopathy. Low selenium concentrations in clozapine-treated patients may be important in the pathogenesis of life threatening cardiac side-effects associated with clozapine. Further clinical studies are being conducted to explore this important clinical observation and its therapeutic implications.
RCT Entities:
AIMS: To compare plasma and red-cell selenium concentrations of schizophrenicpatients treated with clozapine, with healthy controls and patients with mood disorders. METHODS: Plasma and red-cell selenium concentrations were measured in random venous blood samples from four groups: mood disorder (n = 36), schizophrenics treated with clozapine (n = 54), schizophrenics not treated with clozapine (n = 41) and a healthy control group (n = 56). Assays were performed by an independent laboratory that was blinded to the patient groups and specializes in estimating trace metal concentrations. RESULTS:Selenium concentrations in plasma and red cells were found to be significantly lower in schizophrenicpatients treated with clozapine as compared with all other groups. CONCLUSIONS:Selenium is an essential antioxidant. Its deficiency has been implicated in myocarditis and cardiomyopathy. Low selenium concentrations in clozapine-treated patients may be important in the pathogenesis of life threatening cardiac side-effects associated with clozapine. Further clinical studies are being conducted to explore this important clinical observation and its therapeutic implications.
Authors: Stephen J Glatt; Ian P Everall; William S Kremen; Jacques Corbeil; Roman Sásik; Negar Khanlou; Mark Han; Choong-Chin Liew; Ming T Tsuang Journal: Proc Natl Acad Sci U S A Date: 2005-10-13 Impact factor: 11.205
Authors: Maia J Benner; Matt L Settles; Gordon K Murdoch; Ronald W Hardy; Barrie D Robison Journal: Physiol Genomics Date: 2013-06-04 Impact factor: 3.107
Authors: Jiahui Ma; Lailai Yan; Tongjun Guo; Siyu Yang; Chen Guo; Yaqiong Liu; Qing Xie; Jingyu Wang Journal: Int J Environ Res Public Health Date: 2019-10-30 Impact factor: 3.390
Authors: Yasaman Malekizadeh; Gareth Williams; Mark Kelson; David Whitfield; Jonathan Mill; David A Collier; Clive Ballard; Aaron R Jeffries; Byron Creese Journal: Alzheimers Dement (N Y) Date: 2020-08-24